194 related articles for article (PubMed ID: 33786987)
1. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract][Full Text] [Related]
2. The transmembrane protein LRIG2 increases tumor progression in skin carcinogenesis.
Hoesl C; Fröhlich T; Hundt JE; Kneitz H; Goebeler M; Wolf R; Schneider MR; Dahlhoff M
Mol Oncol; 2019 Nov; 13(11):2476-2492. PubMed ID: 31580518
[TBL] [Abstract][Full Text] [Related]
3. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
4. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
[TBL] [Abstract][Full Text] [Related]
5. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.
Billing O; Holmgren Y; Nosek D; Hedman H; Hemmingsson O
Oncogene; 2021 May; 40(21):3707-3718. PubMed ID: 33947959
[TBL] [Abstract][Full Text] [Related]
6. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
7. ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma.
Liu S; Geng R; Lin E; Zhao P; Chen Y
Front Genet; 2021; 12():602160. PubMed ID: 33732282
[TBL] [Abstract][Full Text] [Related]
8. Aryl Hydrocarbon Receptor Defect Attenuates Mitogen-Activated Signaling through Leucine-Rich Repeats and Immunoglobulin-like Domains 1 (LRIG1)-Dependent EGFR Degradation.
Hsu HL; Chen HK; Tsai CH; Liao PL; Chan YJ; Lee YC; Lee CC; Li CH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576152
[TBL] [Abstract][Full Text] [Related]
9. ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis.
Dahlhoff M; Schäfer M; Muzumdar S; Rose C; Schneider MR
Mol Oncol; 2015 Nov; 9(9):1825-33. PubMed ID: 26194695
[TBL] [Abstract][Full Text] [Related]
10. Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion.
Xian W; Rosenberg MP; DiGiovanni J
Oncogene; 1997 Mar; 14(12):1435-44. PubMed ID: 9136987
[TBL] [Abstract][Full Text] [Related]
11. LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.
Li W; Zhou Y
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30487162
[TBL] [Abstract][Full Text] [Related]
12. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.
Yi W; Holmlund C; Nilsson J; Inui S; Lei T; Itami S; Henriksson R; Hedman H
Exp Cell Res; 2011 Feb; 317(4):504-12. PubMed ID: 21087604
[TBL] [Abstract][Full Text] [Related]
13. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.
Lu L; Teixeira VH; Yuan Z; Graham TA; Endesfelder D; Kolluri K; Al-Juffali N; Hamilton N; Nicholson AG; Falzon M; Kschischo M; Swanton C; Wright NA; Carroll B; Watt FM; George JP; Jensen KB; Giangreco A; Janes SM
J Pathol; 2013 Mar; 229(4):608-20. PubMed ID: 23208928
[TBL] [Abstract][Full Text] [Related]
14. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
[TBL] [Abstract][Full Text] [Related]
15. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
[TBL] [Abstract][Full Text] [Related]
16. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
[TBL] [Abstract][Full Text] [Related]
17. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
Miller JK; Shattuck DL; Ingalla EQ; Yen L; Borowsky AD; Young LJ; Cardiff RD; Carraway KL; Sweeney C
Cancer Res; 2008 Oct; 68(20):8286-94. PubMed ID: 18922900
[TBL] [Abstract][Full Text] [Related]
18. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
19. Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is downregulated in Invasive ductal carcinoma and potential prognostic marker of breast cancer.
Piracha ZZ; Saeed U
J Cancer Res Ther; 2023 Oct; 19(7):1870-1879. PubMed ID: 38376291
[TBL] [Abstract][Full Text] [Related]
20. The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation.
Hoesl C; Röhrl JM; Schneider MR; Dahlhoff M
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):958-966. PubMed ID: 29410073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
